Evaxion A (EVAX) Accumulated Depreciation & Amortization (2020 - 2021)

Evaxion A (EVAX) reported Accumulated Depreciation & Amortization of $5.3 million for Q4 2021, up 14902.78% on a YoY basis from N/an in Q4 2020, and up 14902.78% quarter-over-quarter from -$36000.0 in Q4 2020.

Evaxion A (EVAX) Accumulated Depreciation & Amortization (2020 - 2021) Analysis & Trends

Evaxion A has reported Accumulated Depreciation & Amortization for 2 years, with the latest figure at $5.3 million in Q4 2021.

  • For the quarter ending Q4 2021, Accumulated Depreciation & Amortization rose 14902.78% year-over-year to $5.3 million; the trailing twelve-month figure through Dec 2021 stood at $5.3 million (up 14902.78% YoY), and the FY2021 full-year result was $5.3 million, up 14902.78% from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2021 stood at $5.3 million, up from -$36000.0 in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $5.3 million in Q4 2021, with the low at -$36000.0 in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn -
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn -
7 Psyence Biomedical 212.16 Bn 212.16 Bn -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn
9 Abivax 91.96 Bn 91.96 Bn -
10 Regeneron Pharmaceuticals 63.43 Bn 54.67 Bn 3.31 Bn

Historic Data

Download Data
DateValue
Dec 31, 2021 5.33 Mn
Dec 31, 2021 5.33 Mn
Dec 31, 2020 -36,000.00
Dec 31, 2020 -36,000.00